Loading…
← CockpitCompetitor Analysis › NBIX Neurocrine Biosciences, Inc.Open in the cockpit ↗

Neurocrine Biosciences, Inc.NBIXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech developing treatments for neurological and endocrine disorders, led by Ingrezza for tardive dyskinesia and Huntington's chorea.

Momentum strong 77
Mkt cap
$16.5B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$238M
20-day average traded
Fwd P/E
18.0×
forward earnings
ROIC−WACC
+13.5 pp
WACC 6.8%
Hurdle
-24 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · USD$162.86
1D-1.8%
1W-6.6%
1M+14.7%
3M+6.5%
6M+5.3%
YTD+14.8%
1Y+13.4%
ATR %3.3%
Beta0.66
52w lowhigh12.5% off high

What Neurocrine Biosciences does

Biotech developing treatments for neurological and endocrine disorders, led by Ingrezza for tardive dyskinesia and Huntington's chorea.

Sells Ingrezza and Crenessity itself in the US, mostly through specialty pharmacies, with Ingrezza carrying the bulk of the business. It also receives royalties from AbbVie on the endometriosis drug Orilissa and from Mitsubishi Tanabe on Ingrezza in parts of Asia, which help fund its nervous-system pipeline.

Products and services

  • Ingrezza (tardive dyskinesia/chorea)
  • Crenessity (congenital adrenal hyperplasia)
  • Pipeline: schizophrenia, other CNS

Customers

  • Neurologists/psychiatrists treating movement disor
  • Endocrinologists

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Neurological and endocrine drug…

What could go right

  • Ingrezza continued volume/share growth
  • New drug launches (Crenessity ramp)

What could go wrong

  • Ingrezza patent expiration risk (2030s)
  • Pipeline execution risk in CNS trials

Moat: narrow (IP / patents, regulatory licence). Ingrezza's category leadership in tardive dyskinesia is protected by patents into the early 2030s.

Headquarters: San Diego, California, US · Founded: 1992 · Employees: 2,000

Named competitors

Neurocrine Biosciences at a glance

Size Neurocrine Biosciences (NBIX) is a United States Health Care company (Biotechnology) with a market value of $16.5B, the 559th largest of 3,085 United States companies the cockpit tracks. Shares closed at $162.86 on 18 Nov 2026.

Performance Over six months the shares gained 5.3%, against +26.1% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 38.0% over the last twelve months (peer median +22.0%); the operating margin is 24.6% (peer median 20.3%).

Valuation It trades at 18.0× forward earnings against a peer median of 33.9× (4th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -24 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.5 points above its cost of capital (6.8% WACC).

Short interest Short interest is 5.8% of the free float (30 Oct 2026).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 124NBIX 105
Six months, rebased to 100: Neurocrine Biosciences against the median of its 20 peers (local-currency closes).

Neurocrine Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.70B$2.86B$2.36B$1.89B$1.49B
Revenue growth—+21%+25%+27%—
Gross profit$3.57B$2.81B$2.30B$1.83B$1.45B
EBITDA$994M$667M$624M$416M$266M
Net income$702M$479M$341M$250M$154M
Free cash flow$973M$749M$557M$362M$323M
Capital expenditure$26.1M$34.0M$38.2M$28.3M$16.5M
Total debt$392M$471M$496M$460M$280M

Quarterly statements and history in the cockpit →

Neurocrine Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%BBIOELANBNTX1093BMRN2269TECHUTHRHALOKYMR002422KRYSPCVXGMAB1961701548SMMTTWST068270TXGNBIX6-month return →1-month return →
Up and to the right = strong over both horizons. Neurocrine Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×ELAN1093BMRN2269TECHUTHRHALO002422GMAB1961701548068270NBIXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Neurocrine Biosciences is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%ELAN1093BMRN2269TECHUTHRHALO002422KRYSGMAB1961701548068270TXGNBIXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Neurocrine Biosciences is the large dot.

Neurocrine Biosciences competitors and peer comparison

Head to head with its named competitors (NBIX vs ABBV vs TEVA vs BMY)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Neurocrine Biosciences NBIX$16.5B+5%+38%25%18.0×-1.5%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%

How Neurocrine Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Neurocrine Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureNBIXPeer medianRank in peer set
1-month return+14.7%-5.4%4th highest of 21
6-month return+5.3%+26.1%6th lowest of 21
Distance from 52-week high-12.5%-21.5%5th highest of 21
Revenue growth (TTM)+38.0%+22.0%7th highest of 19
Operating margin24.6%20.3%9th highest of 19
Forward P/E18.0×33.9×4th cheapest of 14
Growth the price implies (Req g, 7 yrs)-1.5%12.4%2nd least demanding of 15
Growth delivered (Del g)+22.3%+17.1%5th highest of 15
Hurdle (Req g minus delivered)-23.8 pp-7.5 pp2nd least demanding of 15
ROIC minus cost of capital+13.5 pp-0.5 pp6th highest of 20
EV / EBITDA16.2×20.3×6th cheapest of 13
Net debt / EBITDA-0.3×-0.7×7th least indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%18.0×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%n/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%n/an/an/a
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%26.5×20.8%+30.2%
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%23.9×0.3%+16.5%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%40.9×11.6%+19.5%
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%42.0×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%33.9×10.6%+17.6%
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%

Questions

Who are Neurocrine Biosciences's main competitors?
Named competitors: AbbVie (Austedo) (ABBV), Teva Pharmaceutical (Austedo) (TEVA), Bristol Myers Squibb (Karuna) (BMY). The cockpit's measured peer set (industry) also includes BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), BioNTech SE Sponsored ADR (BNTX), Cspc Pharma (1093.HK), BioMarin Pharmaceutical (BMRN), Wuxi Bio (2269.HK).
Is Neurocrine Biosciences expensive compared with its peers?
On forward p/e it trades at 18.0× against a peer median of 33.9×, 4th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -24 pp: the price already allows for a slowdown.
How has Neurocrine Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +5.3% against +26.1% for the median peer; over one year +13.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.